Vindesine

ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Key facts

Vindesine is a drug catalogued in DrugCentral. It was first approved by the YEAR INTRODUCED in 1979. DrugCentral lists 1 molecular target, including CYP3A4. Recorded indications include Acute lymphoid leukemia, Chronic myeloid leukemia, Malignant melanoma and Malignant tumor of lung.

• Molecular targets: CYP3A4 (1 listed in DrugCentral).
• Indications: Acute lymphoid leukemia, Chronic myeloid leukemia, Malignant melanoma and Malignant tumor of lung.
• ATC code: L01CA03 (Vinca alkaloids and analogues).
• Molecular formula: C43H55N5O7; molecular weight 753.94 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (4)

• Acute lymphoid leukemia
• Chronic myeloid leukemia
• Malignant melanoma
• Malignant tumor of lung

Mechanism & targets

Molecular targets (1)

Target	Gene	Action	Activity
Cytochrome P450 3A4	CYP3A4	unknown	Km 4.61

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1979-01-01	YEAR INTRODUCED	—	—

ATC classification

ATC code	Therapeutic hierarchy
L01CA03	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS › Vinca alkaloids and analogues

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Myelosuppression	1798.6
Bone marrow failure	461.1
Leukopenia	224.3
White blood cell count decreased	180.7
Agranulocytosis	165.4
Neutrophil count decreased	149.0
Febrile neutropenia	139.5
Anaemia	130.7
Pyrexia	99.6
Pneumonia	93.9
Neutropenia	92.4
Aspergillus infection	89.9

Chemical structure

• Molecular formula: C₄₃H₅₅N₅O₇
• Molecular weight: 753.94 g/mol
• CAS number: 53643-48-4
• InChIKey: HHJUWIANJFBDHT-ZVTSDNJWSA-N
• PubChem CID: 40839

CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=CC2=C(C=C1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](O)[C@]1(O)C(N)=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Vindesine used for?

DrugCentral lists the following indications for Vindesine: Acute lymphoid leukemia, Chronic myeloid leukemia, Malignant melanoma and Malignant tumor of lung.

How does Vindesine work?

Its molecular targets in DrugCentral include CYP3A4.

When was Vindesine first approved?

Vindesine was first approved by the YEAR INTRODUCED in 1979.

What is the chemical formula of Vindesine?

Vindesine has the molecular formula C43H55N5O7 and a molecular weight of 753.94 g/mol.

Sources

• DrugCentral drug card 2826 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL238071 — compound record and bioactivity
• PubChem CID 40839 — chemical identifiers
• DrugBank DB00309 — drug record
• FDA UNII RSA8KO39WH — substance identity
• UniProt P08684 (CYP3A4) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.